Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | June 18, 2026 | June 23, 2026 |
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | June 02, 2026 | June 04, 2026 |
| KYNTRA BIO, INC.KYNB · Entity 7431 | Director | June 12, 2026 | June 17, 2026 |
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 19,848 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 19,848 |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 2,927 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18 | Direct | 14,950 |
Reported balance
After 2026-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950 F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.
BIOMARIN PHARMACEUTICAL INC
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,500 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 7,490 · Balance 35,500 F1: Restricted stock units granted on June 2, 2026. Price not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on June 2, 2026. Price not applicable.
KYNTRA BIO, INC.
Report date June 12, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.13 · Expires 2036-06-11 | Direct | 7,000 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 7,000 · Balance 7,000 F1: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.
Neumora Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2036-05-26 | Direct | 80,000 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 80,000 · Balance 80,000 F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PAREXEL INTERNATIONAL CORP
Report date September 29, 2017 · Filed October 04, 2017
Section 16 reporting ended · disclosed 2017-10-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-09-29 transaction · row 1
1 source rowRow 1 · 2017-09-29 · Disposition to issuer · Disposed 6,612 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2022 Filed May 24, 2022 20:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000050 · wf-form4_165342305911473.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000049 · wf-form4_162266438962941.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,686 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000049 · wf-form4_162266438962941.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2021 Filed May 28, 2021 23:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $20.86 | $0.00 |
DisclosureSEC source: 0001209191-21-036678 · doc4.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-05-25 F2 · derivative.exercise_date: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 23:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036678 · doc4.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,955 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 21:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 5,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011306 · doc1.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,470 F1 · price: Restricted stock units granted on May 25, 2021. Price not applicable. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:44 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 8,888 | $0.00 Strike: $56.76 | $0.00 |
DisclosureSEC source: 0001439222-21-000042 · wf-form4_162188902273056.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common stock · 8,888 shares Expires 2031-05-20 F3 · derivative.exercise_date: This option was granted on May 20, 2021. The shares underlying this option vest as to 100% of the underlying shares on May 20, 2022. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:44 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock unit · Derivative | 1,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000042 · wf-form4_162188902273056.xml · derivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,585 Underlying: Common stock · 1,585 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested F2 · derivative.expiration_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 2,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-004525 · doc1.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,350 F1 · price: Restricted stock units granted on February 17, 2021 represent a pro rata share of the 2020 annual award for independent directors and vest on the date immediately prior to the date of the Company's next regular annual meeting of stockholders, the same vesting date for the 2020 annual award for all other independent directors. Read SEC document |
| June 04, 2020 Filed Jun 9, 2020 00:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $32.69 | $0.00 |
DisclosureSEC source: 0001209191-20-035150 · doc4.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2030-06-03 F2 · derivative.exercise_date: Options vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| June 04, 2020 Filed Jun 9, 2020 00:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035150 · doc4.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,255 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000049 · wf-form4_159104592041995.xml · derivative · entry 4 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,878 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000049 · wf-form4_159104592041995.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 1,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000049 · wf-form4_159104592041995.xml · derivative · entry 3 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,686 Underlying: Common stock · 1,686 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 8,096 | $0.00 Strike: $53.35 | $0.00 |
DisclosureSEC source: 0001439222-20-000049 · wf-form4_159104592041995.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,096 Underlying: Common stock · 8,096 shares Expires 2030-05-28 F2 · derivative.exercise_date: This option was granted on May 28, 2020. This option vests as to 100% of the underlying shares on May 28, 2021. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 22:57 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $39.03 | $0.00 |
DisclosureSEC source: 0001209191-19-035652 · doc4.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2029-06-05 F2 · derivative.exercise_date: Options vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 22:57 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035652 · doc4.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,555 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033622 · doc4.xml · derivative · entry 4 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-033622 · doc4.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 1,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033622 · doc4.xml · derivative · entry 3 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878 Underlying: Common stock · 1,878 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 8,919 | $0.00 Strike: $47.91 | $0.00 |
DisclosureSEC source: 0001209191-19-033622 · doc4.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,919 Underlying: Common stock · 8,919 shares Expires 2029-05-29 F2 · derivative.exercise_date: This option was granted on May 29, 2019. The shares underlying this option vest as to 100% of the underlying shares on May 29, 2020. Read SEC document |
| December 06, 2018 Filed Feb 8, 2019 00:54 UTC Amendment | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 3,008 | $0.00 Strike: $40.93 | $0.00 |
DisclosureSEC source: 0001209191-19-008296 · doc4a.xml · derivative · entry 3 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,008 Underlying: Common Stock · 3,008 shares Expires 2028-12-06 F3 · derivative.exercise_date: Options vest on the earlier of June 6, 2019 or the date of next annual meeting of stockholders. Read SEC document |
| December 06, 2018 Filed Feb 8, 2019 00:54 UTC Amendment | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 10,400 | $0.00 Strike: $40.93 | $0.00 |
DisclosureSEC source: 0001209191-19-008296 · doc4a.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,400 Underlying: Common Stock · 10,400 shares Expires 2028-12-06 F2 · derivative.exercise_date: Option vests quarterly over three years from December 5, 2018. Read SEC document |
| December 06, 2018 Filed Feb 8, 2019 00:54 UTC Amendment | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 1,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008296 · doc4a.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,855 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders. Read SEC document |
| December 05, 2018 Filed Dec 7, 2018 23:51 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 3,008 | $0.00 Strike: $41.34 | $0.00 |
DisclosureSEC source: 0001209191-18-061652 · doc4.xml · derivative · entry 3 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,008 Underlying: Common Stock · 3,008 shares Expires 2028-12-05 F3 · derivative.exercise_date: Options vest on the earlier of June 6, 2019 or the date of next annual meeting of stockholders. Read SEC document |
| December 05, 2018 Filed Dec 7, 2018 23:51 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 10,400 | $0.00 Strike: $41.34 | $0.00 |
DisclosureSEC source: 0001209191-18-061652 · doc4.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,400 Underlying: Common Stock · 10,400 shares Expires 2028-12-05 F2 · derivative.exercise_date: Option vests quarterly over three years from December 5, 2018. Read SEC document |
| December 05, 2018 Filed Dec 7, 2018 23:51 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 1,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-061652 · doc4.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,855 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:23 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035070 · doc4.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:23 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 5,700 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001209191-18-035070 · doc4.xml · derivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common stock · 5,700 shares Expires 2028-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:22 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | Disposition to issuerCommon Stock | 6,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-023639 · doc4.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration"). F1 · price: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration"). Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 14:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GrantCommon Stock | 1,823 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-027248 · form4.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,612 F1 · security: Shares of restricted stock awarded pursuant to PAREXEL International Corporation 2015 Stock Incentive Plan. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $50.73 | $0.00 |
DisclosureSEC source: 0001209191-17-040191 · doc4.xml · derivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common stock · 8,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: This option was granted on June 13, 2017. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2018. Read SEC document |
| September 15, 2016 Filed Sep 16, 2016 10:48 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GrantCommon Stock | 2,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-062581 · form4.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,789 F1 · security: Shares of restricted stock awarded pursuant to PAREXEL International Corporation 2015 Stock Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.